XTRA:MRK Earnings and Revenue History March 14th 2025 How Do Unusual Items Influence Profit? For anyone who wants to understand Merck KGaA's profit beyond the statutory numbers, i ...
Full Year 2024 Results Key Financial Results Revenue: €21.2b (flat on FY 2023). Net ...
Merck KGaA on Thursday forecast currency-adjusted operating earnings growth of up to 8%, helped by demand for semiconductor ...
In a report released today, Matthew Weston from UBS maintained a Buy rating on Merck KGaA (0O14 – Research Report), with a price target of ...
Merck KGaA expects earnings and sales growth this year after reporting a rise in annual earnings on temporarily reduced ...
Merck KGaA’s Mavenclad (cladribine) tablets have been recommended by the National Institute for Health and Care Excellence ...
The list price of Mavenclad is around £2,050 per 10mg tablet, although, Merck is providing it to the NHS in England at a ...
Clinical Trials Arena on MSN3d
Merck KGaA’s lupus drug fails in SLE cohort of Phase II trialMerck’s lupus drug enpatoran has failed to meet the primary endpoint in a subgroup of patients, but the drug's development is ...
One of Merck KGaA’s leading immunology assets has flunked a phase 2 lupus trial. | One of Merck KGaA’s leading immunology ...
In a report released today, James Quigley from Goldman Sachs maintained a Buy rating on Merck KGaA (0O14 – Research Report), with a price ...
Germany’s Merck KGaA (MRK: DE) returned to profitable growth in 2024 and delivered on its guidance for the year.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback